A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia
Latest Information Update: 17 Oct 2022
At a glance
- Drugs BAC Charsire Biotechnology (Primary)
- Indications Alzheimer's disease; Vascular dementia
- Focus Therapeutic Use
- Sponsors Charsire Biotechnology Corporation
- 21 Sep 2022 Results published in the Charsire Biotechnology Corporation Media Release.
- 29 Jul 2019 Status changed from recruiting to completed.
- 05 Apr 2017 Status changed from not yet recruiting to recruiting.